Can Wegovy Affect Pregnancy — and Is It Safe to Continue?

What do we actually know about Wegovy and pregnancy outcomes?

The honest starting point is that robust human data on semaglutide use during pregnancy is sparse. Wegovy's clinical trials excluded pregnant participants, so the evidence base draws primarily from animal studies and post-marketing case reports rather than large controlled human trials.

Animal studies are not automatically transferable to humans, but they carry enough weight that regulators take them seriously. Semaglutide has been shown to cause foetal harm in animal models at doses within the range considered relevant to human therapeutic levels, including effects on birth weight and skeletal development. The MHRA Drug Safety Update index reflects ongoing monitoring of GLP-1 medicines, and the current position is that the theoretical risk cannot be dismissed until human data proves otherwise.

On the question of whether Wegovy affects pregnancy in practice, what is known is this: unintended pregnancies can occur more easily on GLP-1 treatment than some patients expect. Semaglutide slows gastric emptying, which can reduce the absorption of oral contraceptive pills. The result is that women who rely on the pill for contraception may have lower circulating hormone levels than they realise. If you are reading about semaglutide and pregnancy because you are already in this situation, that interaction is a plausible contributing factor worth raising with your doctor.

What remains genuinely uncertain is whether brief early exposure, before a pregnancy is detected, carries clinically significant risk. No firm answer exists on that yet. The precautionary guidance stands: stop, report to your care team, and let them advise.

Should you stop Wegovy before trying to conceive, and how long beforehand?

Yes, stopping before a planned pregnancy is strongly recommended. The MHRA advises that women use effective contraception throughout Wegovy treatment and for a wash-out period afterwards before attempting to conceive. The prescribing information for semaglutide specifies a two-month wash-out period after the last dose before trying to become pregnant, reflecting the medicine's relatively long half-life.

This is one of those areas where the instruction sounds straightforward but the practicalities deserve a proper conversation. Your GP, a gynaecologist, or a fertility specialist can factor in your weight-management history, any underlying conditions, and your specific reproductive plans. It is also worth knowing that weight loss itself can affect fertility in both directions, for some women, reaching a healthier weight improves ovulatory function, which is relevant to contraception decisions during treatment.

The NHS England guidance on weight-management injections covers the contraception and conception advice for semaglutide in detail, and it is the most current official UK source on this topic. If you are already reading around the subject of pregnancy after Wegovy, that page covers the post-treatment planning picture more fully.

What about breastfeeding, does Wegovy pass into breast milk?

The available data does not definitively confirm whether semaglutide passes into human breast milk in clinically significant quantities. Animal studies suggest it does transfer, and because a newborn's exposure via milk cannot be considered safe on current evidence, breastfeeding while taking Wegovy is not recommended.

This is not an uncommon situation for medicines: absence of safety data is treated as a reason for caution, not as reassurance. If you are postpartum and considering when it might be appropriate to restart weight-management treatment, that timing question belongs with your GP or prescribing clinician rather than with guidance designed for a general audience. Body weight after pregnancy can be medically significant, and the right moment to address it with medication should factor in your feeding choices, recovery, and overall health.

For a broader picture of how Wegovy works and who it is licensed for outside of pregnancy contexts, that overview covers the full licensed use and eligibility criteria clearly.

If you are currently on Wegovy and not pregnant, what should you know about contraception?

This is a question our prescribers hear regularly, and the answer matters practically. Semaglutide does not appear to reduce the effectiveness of the oral contraceptive pill to the same degree as tirzepatide (NHS guidance notes that the clear interaction evidence applies to tirzepatide, not semaglutide) but slowed gastric emptying is a property shared across GLP-1 medicines, and the full picture for whether semaglutide affects pregnancy risk through contraceptive interactions is still being characterised. The conservative position is to discuss your contraception method with your prescribing clinician if you rely on an oral pill.

Non-oral methods (patches, implants, injections, intrauterine devices) are unaffected by gut motility changes, which is why they are often a cleaner option for women on any GLP-1 treatment who want reliable contraception.

If weight loss on Wegovy restores or improves ovulatory cycles in women who had irregular periods linked to their weight, the effective contraceptive window can shift in ways that are easy to miss. Worth raising with your GP well before it becomes urgent. For anyone thinking through the food and lifestyle side of treatment alongside these considerations, the guidance on what not to eat or drink on Wegovy is a practical companion resource. And if you are still exploring whether Wegovy is the right route for your situation, our free consultation connects you with a GPhC-registered prescriber who can review your full clinical picture the same day.